Your Immune System Is Attacking Itself. Here's the Biological Reason.

HLA-DQ2 is an antigen-presenting molecule. Its job is to display peptides (protein fragments) on the surface of immune cells so T-cells can learn what is dangerous and what is safe. If this presentation system is working properly, your T-cells learn to ignore your own tissues and attack only true invaders.

HLA-DQ2 is carried by roughly 25-30% of people with European ancestry. Here’s the problem: this gene makes your immune system much more likely to misidentify your own proteins as foreign threats. It’s not that the gene is broken; it presents certain self-peptides in a way that looks exactly like dangerous pathogens. Your T-cells learn to attack them.

If you carry HLA-DQ2, your immune system has a fundamental recognition problem. You might feel fine for years. Then an infection, stress, or antigenic trigger causes your T-cells to cross-react against your own tissues. Your joint linings, your gut lining, your thyroid, your neurological tissue, all become targets.

CTLA4 is a checkpoint molecule on T-cells. Its job is to apply the brakes to immune activation. When CTLA4 engages with its partner molecule on regulatory cells, it sends a signal: stop attacking, stand down, this is not a threat. This is how your immune system learns to tolerate your own tissues.

The CTLA4 +49A>G variant is carried by roughly 45% of the population. This variant reduces CTLA4 function, which means your T-cells have weaker brakes. They stay activated longer. They require stronger signals to back off. They’re more likely to keep attacking even when the threat is gone.

With a reduced-function CTLA4 variant, your immune system doesn’t down-regulate properly. You might get a respiratory infection and your immune response never fully resolves. Your T-cells keep circulating, keep looking for targets, keep attacking. Eventually they find self-antigens that cross-react with the pathogen. And autoimmunity begins.

TNF (tumor necrosis factor-alpha) is one of your body’s most powerful inflammatory molecules. In normal amounts, it helps you fight infections and heal injuries. But when it gets too high, it drives systemic inflammation that damages your own tissues.

The TNF -308G>A variant is carried by roughly 30% of people. This variant causes you to produce significantly higher TNF-alpha levels in response to inflammatory triggers. Your baseline inflammatory state is higher. You mount more aggressive inflammatory responses to infections, stress, and immune activation.

If you carry the TNF high-producer variant, your body is primed for excessive inflammation. A single infection or inflammatory challenge can trigger a TNF surge that lasts weeks. This persistent elevation drives autoimmune antibody production and T-cell activation. Your joint inflammation becomes more severe. Your fatigue deepens. Your systemic symptoms intensify.

IL-6 (interleukin-6) is a signaling molecule that tells immune cells to amplify inflammation. It’s the cytokine that turns a local immune response into a systemic one. Without it, you can’t mount a strong defense against pathogens. With too much, you get chronic inflammation and neuroinflammation.

The IL6 -174G>C variant is carried by roughly 40% of the population. The C allele shifts your baseline toward higher IL-6 production. Your body interprets challenges as more severe. Your inflammatory response spreads faster through your bloodstream. Inflammation that should stay local becomes systemic.

With the high-IL6 variant, a localized infection becomes full-body inflammation. Stress triggers weeks of elevated IL-6. This persistent elevation drives autoimmune T-cell activation and antibody production. You experience more severe joint pain, worse brain fog, more profound fatigue. Your baseline inflammatory state is simply higher.

PTPN22 is a phosphatase that helps regulate T-cell signaling. It’s part of the molecular machinery that decides whether a T-cell should activate or stay quiet. PTPN22 essentially tells T-cells when to listen to their own internal wisdom and when to ignore false alarms.

The PTPN22 1858C>T variant is associated with increased autoimmune risk across multiple conditions including type 1 diabetes, rheumatoid arthritis, and lupus. This variant subtly shifts T-cell signaling toward greater reactivity, making your T-cells more likely to respond to self-antigens and cross-react against your own tissues. The effect is population-dependent and not uniformly penetrant, but carriers show consistently elevated autoimmune disease risk.

If you carry the PTPN22 variant, your T-cells have a lower activation threshold. They respond more aggressively to antigenic stimulation. They’re more likely to cross-react with self-antigens. This is why infections can trigger autoimmune onset in PTPN22 carriers; a strong immune response to a pathogen can lead to T-cells attacking similar structures in your own tissues.

IRF5 (interferon regulatory factor 5) is a transcription factor that controls interferon production and innate immune activation. Interferons are powerful antiviral molecules that strengthen immune defenses. IRF5 determines how aggressively your body launches these antiviral responses.

IRF5 genetic variants increase the risk of lupus, rheumatoid arthritis, and other systemic autoimmune conditions through a mechanism of heightened interferon signaling. Carriers of the risk-associated IRF5 variants show exaggerated type I interferon responses to viral triggers and produce more interferon-alpha and interferon-beta. This creates a state of chronic interferon activation that drives autoimmune T-cell and B-cell responses.

If you carry IRF5 variants associated with autoimmunity, your body overresponds to viral infections. A single respiratory virus can trigger a prolonged interferon surge that lasts weeks. This persistent interferon activation promotes autoimmune antibody production and drives systemic inflammation. Your body becomes trapped in an antiviral state even after the virus is cleared.